HLA-B

Across TCGA pan-cancer cohorts, HLA-B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HLA-B data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher HLA-B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-B expression acts as an unfavorable survival marker.

KIRC, STAD, and KIRP are the cancer types where HLA-B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	48	view →
STAD	OS	Median	II,III,IV	0.342	0.680	<.001	26	view →
KIRP	DFS	Median	All	0.038	0.920	<.001	22	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	III,IV	0.124	0.632	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HLA-B–KIRC (OS)

Open the KIRC breakdown →